Sector News

Perrigo rejects Mylan’s higher bid

April 30, 2015
Life sciences
Perrigo is still standing strong against Mylan’s takeover attempt, rejecting the latest offer of $75 in cash and 2.3 shares for every share of Perrigo on the basis that is undervalues the business.
 
The Dublin, Ireland-based group is arguing that the new offer remains under Mylan’s original bid value of $205 per share, because the latter’s stock was subsequently inflated by speculation over Teva’s interest in acquiring the firm.
 
“Today’s announcement from Mylan continues to propose a price lower than the previously rejected proposal,” Perrigo said, insisting that “based on Mylan’s unaffected price of $55.31 per share on March 10, 2015, the last day of trading prior to widespread public speculation that Teva was considering an offer for Mylan, the value of the revised Offer is $202.20 per Perrigo share”.
 
Mylan is desperate to complete its plans to acquire Perrigo because that would protect it from being snapped up by Teva.
 
Pen wars
Meanwhile the growing spat between Teva and Mylan chiefs continues to be aired in public. Mylan head Robert Coury sent Teva chief Erez Vigodman a hugely critical letter outlining his objection to the move, highlighting the latter’s “poor record of delivering sustainable shareholder value”.
 
Now Teva has retaliated with a responding letter, slamming Coury for his “fundamentally distorted picture” of Teva and asserting that “stakeholders do not support, or benefit from, mudslinging, mischaracterization, rehashing of history or selective presentation of facts”. 
 
“Instead, I would prefer to return the dialogue to the significant value creation opportunity that a combination of Teva and Mylan represents,” Vigodman wrote. In a further dig, he notes “I fully agree with you that it would have been preferable to have engaged in a private discussion to explore this transaction. However, you left us no choice but to make our proposal public after you publicly rejected a potential offer before it had even been made”.
 
By Selina McKee
 
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).